000143334 001__ 143334
000143334 005__ 20240229112548.0
000143334 0247_ $$2doi$$a10.3390/cancers11030415
000143334 0247_ $$2pmid$$apmid:30909610
000143334 0247_ $$2altmetric$$aaltmetric:58531328
000143334 037__ $$aDKFZ-2019-00924
000143334 041__ $$aeng
000143334 082__ $$a610
000143334 1001_ $$0P:(DE-He78)6ea02cd0867abd195dedd893b73bb513$$aYu, Haixin$$b0$$eFirst author$$udkfz
000143334 245__ $$aCirculating MicroRNA Biomarkers for Lung Cancer Detection in East Asian Populations.
000143334 260__ $$aBasel$$bMDPI$$c2019
000143334 3367_ $$2DRIVER$$aarticle
000143334 3367_ $$2DataCite$$aOutput Types/Journal article
000143334 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1562074676_20017$$xReview Article
000143334 3367_ $$2BibTeX$$aARTICLE
000143334 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143334 3367_ $$00$$2EndNote$$aJournal Article
000143334 520__ $$aLung cancer (LC) is the leading cause of cancer-related death in Eastern Asia. The prognosis of LC highly depends on tumor stages and early detection could substantially reduce LC mortality. Accumulating evidence suggested that circulating miRNAs in plasma or serum may have applications in early LC detection. We thus conducted a systematic literature review on the diagnostic value of miRNAs markers for LC in East Asian populations.PubMed and ISI Web of Knowledge were searched to retrieve relevant articles published up to 17 September 2018. Information on study design, population characteristics, investigated miRNAs and diagnostic accuracy (including sensitivity, specificity and area under the curve (AUC)) were independently extracted by two reviewers.Overall, 46 studies that evaluated a total of 88 miRNA markers for LC diagnosis in East Asian populations were identified. Sixteen of the 46 studies have incorporated individual miRNA markers as panels (with 2⁻20 markers). Three promising miRNA panels with ≥90% sensitivity and ≥90% specificity were discovered, two of which were externally validated. Diagnostic performance of circulating miRNAs in East Asian populations was comparable to previously summarized performance in Western populations. Forty-four miRNAs were reported in both populations. No major differences in diagnostic performance by ethnicity of the same miRNA was observed.Circulating miRNAs or miRNA panels, possibly in combination with other promising molecular markers including epigenetic and genetic markers, may be promising candidates for noninvasive LC early detection. However, large studies with samples collected prospectively in true screening settings are required to validate the promising markers or marker panels.
000143334 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143334 588__ $$aDataset connected to CrossRef, PubMed,
000143334 7001_ $$0P:(DE-He78)e2927c4f5c050e0ad98ebb65eebe0d56$$aGuan, Zhong$$b1$$udkfz
000143334 7001_ $$0P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a$$aCuk, Katarina$$b2$$udkfz
000143334 7001_ $$0P:(DE-He78)6a8f87626cb610618a60d742677284cd$$aZhang, Yan$$b3$$udkfz
000143334 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$eLast author$$udkfz
000143334 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers11030415$$gVol. 11, no. 3, p. 415 -$$n3$$p415$$tCancers$$v11$$x2072-6694$$y2019
000143334 909CO $$ooai:inrepo02.dkfz.de:143334$$pVDB
000143334 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6ea02cd0867abd195dedd893b73bb513$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143334 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e2927c4f5c050e0ad98ebb65eebe0d56$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143334 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000143334 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6a8f87626cb610618a60d742677284cd$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000143334 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000143334 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143334 9141_ $$y2019
000143334 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2017
000143334 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143334 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143334 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143334 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143334 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000143334 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000143334 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000143334 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000143334 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143334 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143334 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143334 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143334 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143334 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143334 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2017
000143334 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000143334 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000143334 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000143334 980__ $$ajournal
000143334 980__ $$aVDB
000143334 980__ $$aI:(DE-He78)C070-20160331
000143334 980__ $$aI:(DE-He78)C120-20160331
000143334 980__ $$aI:(DE-He78)L101-20160331
000143334 980__ $$aUNRESTRICTED